Related Experiment Video
Updated: Aug 19, 2026
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
Phase II study of bryostatin 1 in patients with relapsed multiple myeloma
M L Varterasian1, P A Pemberton, K Hulburd
1Karmanos Cancer Institute and Wayne State University, Detroit, MI, USA. mary.varterasian@pfizer.com
Abstract:
Bryostatin 1, a macrocyclic lactone isolated from the marine bryozoan Bugula neritina, is a protein kinase C (PKC) modulator which has shown both preclinical and clinical activity in lymphoid malignancies. We conducted a phase II trial of bryostatin 1 administered at a dose of 120 microg/m2 by 72-h continuous infusion every 2 weeks in patients with relapsed multiple myeloma. Treatment was well tolerated with myalgias constituting the primaray toxicity. There were no responses in nine evaluable patients. The preclinical anti-lymphoid activity is strong enough to support further exploration of bryostatin 1 in different schedules and in combination therapy for multiple myeloma.
Insights
Bryostatin 1, a protein kinase C modulator, was tested in relapsed multiple myeloma patients. The treatment was well-tolerated but showed no responses, suggesting further research in combination therapy.
Area of Science:
- Marine natural products
- Pharmacology
- Oncology
Background:
- Bryostatin 1 is a marine-derived macrocyclic lactone.
- It modulates protein kinase C (PKC).
- Bryostatin 1 has demonstrated preclinical and clinical activity in lymphoid malignancies.
Purpose of the Study:
- To evaluate the efficacy and tolerability of bryostatin 1 in patients with relapsed multiple myeloma.
Main Methods:
- A phase II clinical trial was conducted.
- Bryostatin 1 was administered at 120 microg/m2 via 72-hour continuous infusion every 2 weeks.
- Nine evaluable patients with relapsed multiple myeloma were enrolled.
Main Results:
- The treatment was well-tolerated, with myalgias as the primary toxicity.
- No objective responses were observed in the nine evaluable patients.
Conclusions:
- While well-tolerated, bryostatin 1 did not demonstrate efficacy as a single agent in this patient population.
- The preclinical anti-lymphoid activity warrants further investigation of bryostatin 1 in different dosing schedules and combination therapies for multiple myeloma.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
04:11A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)
Published on: June 9, 2026